Population and event criteria p-Value HR (95% CI) No. Patients  No. Events
Node status ER Status Event
1 Nm ER+ AE <0.0001 1.40 (1.30-1.52) 2274 769
2 Nm ERm AE <0.0001 1.32 (1.23-1.40) 3013 1076
3 Nm ER+ MR <0.0001 1.46 (1.33-1.62) 1813 463
4 Nm ERm MR <0.0001 1.37 (1.26-1.48) 2413 658
5 N- ER+ AE <0.0001 1.45 (1.30-1.61) 1357 404
6 N- ERm AE <0.0001 1.33 (1.21-1.45) 1760 568
7 N- ER+ MR <0.0001 1.48 (1.31-1.69) 1176 272
8 N- ERm MR <0.0001 1.34 (1.20-1.49) 1539 385
9 N+ ERm MR 0.0001 1.33 (1.15-1.53) 643 217
10 N+ ERm AE 0.0008 1.21 (1.08-1.36) 816 376
11 N+ ER+ MR 0.0009 1.34 (1.13-1.60) 506 162
12 N+ ER+ AE 0.0051 1.22 (1.06-1.39) 640 278
13 N+ ER- MR 0.2322 1.21 (0.89-1.65) 133 55
14 N+ ER- AE 0.2566 1.14 (0.91-1.44) 172 98
15 Nm ER- AE 0.3084 1.07 (0.94-1.23) 711 300
16 N- ER- MR 0.4299 0.91 (0.73-1.15) 347 111
17 Nm ER- MR 0.4505 1.07 (0.90-1.26) 578 191
18 N- ER- AE 0.9803 1.00 (0.82-1.22) 383 159
Node or ER status (+: positive, -: negative, m: mixed); AE: any event; MR: metastatic relapse; HR: hazards ratio
Table 1: Prognostic impact of AURKA expression level in 18 possible pools corresponding to every combination of populations (nodal and estrogen receptor status).